153 related articles for article (PubMed ID: 35359970)
21. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
[TBL] [Abstract][Full Text] [Related]
22. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.
Liu J; Wei Y; Wu Y; Li J; Sun J; Ren G; Li H
Front Immunol; 2021; 12():657950. PubMed ID: 33936088
[TBL] [Abstract][Full Text] [Related]
23. Expression profile of Toll‑like receptors in human breast cancer.
Shi S; Xu C; Fang X; Zhang Y; Li H; Wen W; Yang G
Mol Med Rep; 2020 Feb; 21(2):786-794. PubMed ID: 31789409
[TBL] [Abstract][Full Text] [Related]
24. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.
Egelston CA; Avalos C; Tu TY; Rosario A; Wang R; Solomon S; Srinivasan G; Nelson MS; Huang Y; Lim MH; Simons DL; He TF; Yim JH; Kruper L; Mortimer J; Yost S; Guo W; Ruel C; Frankel PH; Yuan Y; Lee PP
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465302
[TBL] [Abstract][Full Text] [Related]
25. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
26. MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis.
Li S; Fang Y
Med Sci Monit; 2022 Jan; 28():e934597. PubMed ID: 35091527
[TBL] [Abstract][Full Text] [Related]
27. JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor.
Liu Q; Ai B; Kong X; Wang X; Qi Y; Wang Z; Fang Y; Wang J
Int Immunopharmacol; 2021 Jan; 90():107186. PubMed ID: 33290964
[TBL] [Abstract][Full Text] [Related]
28. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.
Takeshita T; Yan L; Asaoka M; Rashid O; Takabe K
Sci Rep; 2019 Nov; 9(1):16942. PubMed ID: 31729458
[TBL] [Abstract][Full Text] [Related]
29. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
30. Exploring immune-related genes with prognostic value in microenvironment of breast cancer from TCGA database.
Yang H; Zhao K; Kang H; Wang M; Wu A
Medicine (Baltimore); 2020 Apr; 99(14):e19561. PubMed ID: 32243373
[TBL] [Abstract][Full Text] [Related]
31. The Role of 5-HTR6 in Mossy Fiber Sprouting: Activating Fyn and p-ERK1/2 in Pilocarpine-Induced Chronic Epileptic Rats.
Lin W; Huang W; Chen S; Lin M; Huang Q; Huang H
Cell Physiol Biochem; 2017; 42(1):231-241. PubMed ID: 28535499
[TBL] [Abstract][Full Text] [Related]
32. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
33. LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
Hou MF; Chen PM; Chu PY
BMC Cancer; 2018 Feb; 18(1):219. PubMed ID: 29471794
[TBL] [Abstract][Full Text] [Related]
34. A bioinformatics analysis of zinc finger protein family reveals potential oncogenic biomarkers in breast cancer.
An G; Feng L; Hou L; Li X; Bai J; He L; Gu S; Zhao X
Gene; 2022 Jun; 828():146471. PubMed ID: 35378249
[TBL] [Abstract][Full Text] [Related]
35. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
36. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
37. A signature of immune function genes associated with recurrence-free survival in breast cancer patients.
Ascierto ML; Kmieciak M; Idowu MO; Manjili R; Zhao Y; Grimes M; Dumur C; Wang E; Ramakrishnan V; Wang XY; Bear HD; Marincola FM; Manjili MH
Breast Cancer Res Treat; 2012 Feb; 131(3):871-80. PubMed ID: 21479927
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.
Kumari K; Das B; Adhya AK; Rath AK; Mishra SK
Sci Rep; 2019 Feb; 9(1):1974. PubMed ID: 30760814
[TBL] [Abstract][Full Text] [Related]
39. Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts.
Barone I; Vircillo V; Giordano C; Gelsomino L; Győrffy B; Tarallo R; Rinaldi A; Bruno G; Caruso A; Romeo F; Bonofiglio D; Andò S; Catalano S
Cancer Lett; 2018 Nov; 437():89-99. PubMed ID: 30176263
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
